New pain block study aims to cut opioid use after spinal fusion

NCT ID NCT07228039

Not yet recruiting Symptom relief Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a specific nerve block (ESP block) using bupivacaine can reduce pain and opioid use after spinal fusion surgery. 75 adults undergoing cervical or lumbar fusion will be randomly assigned to receive either plain bupivacaine or a mix with liposomal bupivacaine. Researchers will measure pain scores, opioid consumption, and how quickly patients can leave the hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bupivacaine (plain and liposomal)
What this could lead to: If successful, this could provide a better way to manage pain after spinal fusion, reducing the need for opioids and shortening hospital stays.
What could go wrong: This is a small, early-phase trial (75 people) testing a well-known drug, so the improvement may be modest. Results may not apply to all patients or surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTOPERATIVE PAIN

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.